Cost Effectiveness Analysis of The Use of Daclatasvir for the Treatment of Hepatitis C Virus (Hcv) Genotypes 3 in Cirrhotic Patients Within the Italian National Health Service
Abstract
Authors
U Restelli M Bonfanti A Alberti A Lazzarin C Nappi D Croce